Roche presents new data demonstrating the potential benefit of glofitamab and Lunsumio as fixed-duration, off-the-shelf treatment options for lymphoma December 12, 2022January 20, 2023 by / Share This.....LinkedinTwitterFacebookGoogleEmailRelated News: New pivotal data demonstrate clinical benefit of…New pivotal data demonstrate clinical benefit of…New and updated data for Roche's fixed-duration…New data for Roche’s Columvi and Lunsumio presented…FDA grants priority review to Roche’s bispecific…Roche presents new data at CTAD, demonstrating its…
